Fzata, Inc., has announced the appointment of a new independent member to the board of directors.

The new board member, Gianna Arnold, is counsel with Saul Ewing, LLP and CEO of NuMoon Technologies, LLC. Gianna is a veteran corporate and transactional attorney with deep biopharma expertise, bringing to the board extensive experience in negotiating strategic alliances as well as conducting due diligence analysis for mergers, acquisitions, licensing, and investments.

"Gianna has been instrumental on our business advisory committee, and her extensive transactional experience will be invaluable as we pursue strategic pharma partnerships and prepare for our next equity financing round," said Chairman and CEO of Fzata, Dr Zhiyong Yang.

Arnold has assisted clients in the life sciences for over 30 years, providing IP and transactional services. She was named to The Best Lawyers in America list for Biotechnology and Life Sciences, 2016 to 2023, as well as Chambers USA "America's Leading Lawyers in Intellectual Property" list from 2016 to present. In addition, she brings valuable past experience as an entrepreneur and corporate executive at NuMoon.

"I am very excited to fill this position at Fzata and provide transactional insight," said  Arnold. "I have worked extensively with the company CEO on corporate strategy since its spinout from the University of Maryland Baltimore. I have had the privilege of observing Fzata's remarkable growth and believe their oral biologics platform holds extraordinary potential to transform patient care," she added.